Table 2.
Distribution of clinical characteristics by combination antiretroviral therapy (ART) initiation among HIV/AIDS patients eligible to start therapy, Kwara and Niger states of Nigeria, 2009–2011.
| No ARTa | ART in 90 days | Combined | P-value | |
|---|---|---|---|---|
| (n=305) | (n=869) | (n=1174) | ||
| Height (cm)b | 162 (156, 169) | 162 (156, 167) | 162 (156, 167) | 0.6 |
| Missing, n (%)c | 110 (36.1%) | 197 (22.7%) | 307 (26.1%) | |
| Weight (kg)b | 51 (45, 60) | 53 (47, 60) | 52 (46, 60) | 0.06 |
| Missing, n (%)c | 38 (12.5%) | 25 (2.9%) | 63 (5.4%) | |
| Body mass index (kg/m2)b | 19.3 (17.1, 21.9) | 20.3 (18.3, 22.5) | 20.1 (18.1, 22.4) | 0.001 |
| Missing, n (%)c | 114 (37.4%) | 201 (23.1%) | 315 (26.8%) | |
| Functional status, n (%) | <0.001 | |||
| Bedridden | 14 (4.8%) | 13 (1.5%) | 27 (2.3%) | |
| Ambulatory | 39 (13.4%) | 72 (8.3%) | 111 (9.6%) | |
| Working | 237 (81.7%) | 778 (90.2%) | 1015 (88.0%) | |
| Missingc | 15 (4.9%) | 6 (0.7%) | 21 (1.8%) | |
| CD4+ count (cells/μL)*b | 149 (69, 282) | 159 (86, 250) | 156 (81, 257) | 0.9 |
| CD4+ count category, n (%) | ||||
| ≤50/μL | 45 (18.2%) | 99 (11.9%) | 144 (13.4%) | |
| 51–200 | 104 (42.1%) | 430 (51.8%) | 534 (49.6%) | |
| 201–350 | 71 (28.7%) | 243 (29.3%) | 314 (29.2%) | |
| >350 | 27 (10.9%) | 58 (7.0%) | 85 (7.9%) | |
| Missingc | 58 (19.0%) | 39 (4.5%) | 97 (8.3%) | |
| Hemoglobin (g/dL)b | 10.2 (8.8, 11.8) | 10.3 (9, 11.7) | 10.2 (9, 11.7) | 0.6 |
| Hemoglobin category, n(%) | ||||
| <8 g/dL | 31 (15.7%) | 98 (12.6%) | 129 (13.3%) | |
| 8–10 g/dL | 63 (32.0%) | 248 (32.0%) | 311 (32.0%) | |
| >10 g/dL | 103 (52.3%) | 430 (55.4%) | 533 (54.8%) | |
| Missing | 108 (35.4%) | 93 (10.7%) | 201 (17.1%) | |
| Creatinine (mg/dL)b | 0.8 (0.6, 1.2) | 0.8 (0.6, 1.1) | 0.8 (0.6, 1.1) | 0.7 |
| Missing, n (%)c | 186 (61.0%) | 596 (68.6%) | 782 (66.6%) | |
| WHO clinical stage, n (%) | 0.003 | |||
| I | 37 (12.6%) | 162 (18.7%) | 199 (17.2%) | |
| II | 39 (13.3%) | 140 (16.2%) | 179 (15.4%) | |
| III | 194 (66.0%) | 527 (60.9%) | 721 (62.2%) | |
| IV | 24 (8.2%) | 36 (4.2%) | 60 (5.2%) | |
| Missingc | 11 (3.6%) | 4 (0.5%) | 15 (1.3%) | |
| 1-year mortalityd | 21 (6.9%) | 25 (2.9%) | 46 (3.9%) | 0.003 |
| 1-year loss to follow upd | 119 (39.0%) | 249 (28.7%) | 368 (31.3%) | 0.001 |
WHO = The World Health Organization.
a
Includes 256 patients not initiating treatment prior to database cut date, and 49 initiating >90 days from enrollment.
b
Continuous variables are reported as medians (interquartile range).
c
Percentages are computed using the number of patients with a non-missing value.
d
Mortality and loss to follow up are at 1 year post-enrollment.